JP2016536005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536005A5 JP2016536005A5 JP2016543983A JP2016543983A JP2016536005A5 JP 2016536005 A5 JP2016536005 A5 JP 2016536005A5 JP 2016543983 A JP2016543983 A JP 2016543983A JP 2016543983 A JP2016543983 A JP 2016543983A JP 2016536005 A5 JP2016536005 A5 JP 2016536005A5
- Authority
- JP
- Japan
- Prior art keywords
- cell population
- test cell
- mitochondrial
- contacting
- outer membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 27
- 230000002438 mitochondrial effect Effects 0.000 claims description 15
- 230000008823 permeabilization Effects 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 101150082208 DIABLO gene Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 3
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 claims description 2
- 102000018832 Cytochromes Human genes 0.000 claims description 2
- 108010052832 Cytochromes Proteins 0.000 claims description 2
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 claims description 2
- 231100001143 noxa Toxicity 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 238000010212 intracellular staining Methods 0.000 claims 1
- 238000012758 nuclear staining Methods 0.000 claims 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 14
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361879869P | 2013-09-19 | 2013-09-19 | |
| US61/879,869 | 2013-09-19 | ||
| PCT/US2014/056284 WO2015042249A1 (en) | 2013-09-19 | 2014-09-18 | Methods of bh3 profiling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019188457A Division JP2020012850A (ja) | 2013-09-19 | 2019-10-15 | Ｂｈ３プロファイリングの方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536005A JP2016536005A (ja) | 2016-11-24 |
| JP2016536005A5 true JP2016536005A5 (enExample) | 2017-11-02 |
| JP6663852B2 JP6663852B2 (ja) | 2020-03-13 |
Family
ID=52689380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016543983A Active JP6663852B2 (ja) | 2013-09-19 | 2014-09-18 | Ｂｈ３プロファイリングの方法 |
| JP2019188457A Withdrawn JP2020012850A (ja) | 2013-09-19 | 2019-10-15 | Ｂｈ３プロファイリングの方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019188457A Withdrawn JP2020012850A (ja) | 2013-09-19 | 2019-10-15 | Ｂｈ３プロファイリングの方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10739333B2 (enExample) |
| EP (1) | EP3047276B1 (enExample) |
| JP (2) | JP6663852B2 (enExample) |
| AU (1) | AU2014323526B2 (enExample) |
| CA (1) | CA2922503C (enExample) |
| WO (1) | WO2015042249A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1590363A4 (en) | 2002-09-09 | 2006-11-02 | Dana Farber Cancer Inst Inc | BH3-PEPTIDES AND METHOD FOR THEIR USE |
| EP2008106A2 (en) | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| WO2011143660A2 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| DK2571503T3 (en) | 2010-05-14 | 2015-04-20 | Dana Farber Cancer Inst Inc | COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS |
| WO2011143657A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
| US10393733B2 (en) | 2012-09-19 | 2019-08-27 | Dana-Farber Cancer Institute, Inc. | Dynamic BH3 profiling |
| KR20160034379A (ko) | 2013-07-25 | 2016-03-29 | 다나-파버 캔서 인스티튜트 인크. | 전사 인자의 억제제 및 그의 용도 |
| EP3047276B1 (en) | 2013-09-19 | 2023-06-14 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
| KR20160072261A (ko) | 2013-11-08 | 2016-06-22 | 다나-파버 캔서 인스티튜트 인크. | 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법 |
| EP3099693A4 (en) | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| KR20160115953A (ko) | 2014-01-31 | 2016-10-06 | 다나-파버 캔서 인스티튜트 인크. | 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도 |
| WO2015131113A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| CA2955074A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| BR112017002190A2 (pt) | 2014-08-08 | 2017-11-21 | Dana Farber Cancer Inst Inc | derivados de di-hidropteridinona e usos dos mesmos |
| CN107635979A (zh) | 2014-10-27 | 2018-01-26 | 腾沙治疗公司 | 溴结构域抑制剂 |
| KR20170126867A (ko) | 2015-01-12 | 2017-11-20 | 유트로픽스 파마슈티컬스, 인크. | 암 치료를 안내하기 위한 컨텍스트 의존성 진단 검사 |
| MX2017013383A (es) | 2015-04-20 | 2017-12-07 | Tolero Pharmaceuticals Inc | Prediccion de respuesta a alvocidib mediante perfilado mitocondrial. |
| EP3289094B1 (en) | 2015-04-27 | 2024-06-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
| MX380798B (es) | 2015-05-18 | 2025-03-12 | Sumitomo Pharma Oncology Inc | Profármacos de alvocidib que tienen una biodisponibilidad aumentada. |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| JP7083497B2 (ja) | 2015-08-03 | 2022-06-13 | スミトモ ファーマ オンコロジー， インコーポレイテッド | がんの処置のための併用療法 |
| CA2996974A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| JP2018526424A (ja) | 2015-09-11 | 2018-09-13 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用 |
| RU2742035C2 (ru) | 2015-11-25 | 2021-02-01 | Дана-Фарбер Кэнсер Инститьют, Инк. | Бивалентные ингибиторы бромодоменов и пути их применения |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| EP3362471B1 (en) | 2016-12-19 | 2021-11-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Profiling peptides and methods for sensitivity profiling |
| US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
| CA3119807A1 (en) | 2018-12-04 | 2020-06-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
| US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| EP0669836B1 (en) | 1992-11-13 | 1996-07-03 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| CN1208438A (zh) | 1995-07-28 | 1999-02-17 | 玛丽·柯里癌症治疗中心 | 转运蛋白及其应用 |
| AU716818B2 (en) | 1995-10-24 | 2000-03-09 | Sangstat Medical Corporation | Anti alpha-galactosyl screening technique |
| US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US7064193B1 (en) | 1997-09-17 | 2006-06-20 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic molecules |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| EP1210098A1 (en) | 1999-04-07 | 2002-06-05 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| WO2001012661A2 (en) | 1999-08-16 | 2001-02-22 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health | RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS |
| WO2002020568A2 (en) | 2000-09-06 | 2002-03-14 | Abbott Laboratories | Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins |
| US20020115613A1 (en) | 2001-02-16 | 2002-08-22 | Kumar M. Vijay | Treatment of prostate cancer |
| WO2003040168A2 (en) | 2001-11-06 | 2003-05-15 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
| AU2002226211A1 (en) | 2001-12-21 | 2003-07-15 | Arius Research, Inc. | Individualized anti-cancer antibodies |
| EP1590363A4 (en) * | 2002-09-09 | 2006-11-02 | Dana Farber Cancer Inst Inc | BH3-PEPTIDES AND METHOD FOR THEIR USE |
| US20070032417A1 (en) | 2002-12-24 | 2007-02-08 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| JP2006520606A (ja) | 2003-03-19 | 2006-09-14 | アルファ ワッサーマン インコーポレイテッド | 細胞内成分の分離および蓄積、およびそれに由来するタンパク質 |
| CN103467588B (zh) | 2003-11-05 | 2016-12-28 | 达纳-法伯癌症研究所股份有限公司 | 稳定的α螺旋肽及其用途 |
| US7714005B2 (en) | 2004-12-22 | 2010-05-11 | The Ohio State University Research Foundation | Small molecule Bcl-xL/Bcl-2 binding inhibitors |
| JP2005130867A (ja) | 2005-02-16 | 2005-05-26 | Mitokor | ミトコンドリア内カルシウムを使用するスクリーニングアッセイ |
| WO2006099667A1 (en) * | 2005-03-21 | 2006-09-28 | The Walter And Eliza Hall Institute Of Medical Research | Prophylactic and therapeutic agents and uses therefor |
| WO2007016254A2 (en) * | 2005-07-27 | 2007-02-08 | The Board Of Trustees Of The University Of Arkansas | Antineoplastic activities of ellipticine and its derivatives |
| EP2008106A2 (en) * | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| US8518635B2 (en) | 2006-06-12 | 2013-08-27 | The J. David Gladstone Institutes | Regulation of protein activity by reversible acetylation |
| KR100786759B1 (ko) | 2006-07-07 | 2007-12-18 | 김현기 | Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물 |
| US9360473B2 (en) * | 2006-08-16 | 2016-06-07 | Eutropics Pharmaceuticals, Inc. | Assay system to identify therapeutic agents |
| WO2008152405A2 (en) | 2007-06-15 | 2008-12-18 | The Queen's University Of Belfast | Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases |
| WO2009036092A2 (en) | 2007-09-10 | 2009-03-19 | University Of Massachusetts | Mitochondria-targeted anti-tumor agents |
| EP2208061B1 (en) | 2007-09-26 | 2017-11-08 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| JP2009240173A (ja) | 2008-03-28 | 2009-10-22 | Univ Of Tokushima | パーキン蛋白の新規糖化因子 |
| KR20120025601A (ko) | 2009-06-11 | 2012-03-15 | 미네르바 바이오테크놀로지 코포레이션 | 줄기 세포 및 전구 세포를 배양하는 방법 |
| WO2010147961A1 (en) * | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
| US20130122492A1 (en) | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
| JP2015519565A (ja) | 2012-05-10 | 2015-07-09 | ユートロピクス ファーマシューティカルズ， インコーポレイテッド | がんに対する補助的機能診断テスト |
| US20150322479A1 (en) | 2012-06-20 | 2015-11-12 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
| US10393733B2 (en) * | 2012-09-19 | 2019-08-27 | Dana-Farber Cancer Institute, Inc. | Dynamic BH3 profiling |
| JP6327662B2 (ja) | 2012-09-26 | 2018-05-23 | 学校法人藤田学園 | 細胞表面タンパクを抗原とする抗体を測定する方法 |
| US20160178612A1 (en) | 2013-07-18 | 2016-06-23 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
| EP3047276B1 (en) * | 2013-09-19 | 2023-06-14 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
| EP3289094B1 (en) | 2015-04-27 | 2024-06-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
| US11092602B2 (en) | 2015-07-06 | 2021-08-17 | Whitehead Institute For Biomedical Research | Methods and compositions relating to proteasome inhibitor resistance |
| US20220163510A1 (en) | 2019-02-26 | 2022-05-26 | Dana-Farber Cancer Institute, Inc. | Live cell imaging dynamic bh3 profiling |
-
2014
- 2014-09-18 EP EP14845952.2A patent/EP3047276B1/en active Active
- 2014-09-18 CA CA2922503A patent/CA2922503C/en active Active
- 2014-09-18 JP JP2016543983A patent/JP6663852B2/ja active Active
- 2014-09-18 AU AU2014323526A patent/AU2014323526B2/en active Active
- 2014-09-18 WO PCT/US2014/056284 patent/WO2015042249A1/en not_active Ceased
- 2014-09-18 US US15/022,987 patent/US10739333B2/en active Active
-
2019
- 2019-10-15 JP JP2019188457A patent/JP2020012850A/ja not_active Withdrawn
-
2020
- 2020-07-02 US US16/919,173 patent/US11867687B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536005A5 (enExample) | ||
| JP2015531606A5 (enExample) | ||
| Sun et al. | Peptide-based imaging agents for cancer detection | |
| CY1123747T1 (el) | Χιμαιρικα μορια τελεστες με σημανση και υποδοχεις αυτων | |
| MX2022004293A (es) | Sistema y metodo para matriz de sensores de corona de proteinas para la deteccion temprana de enfermedades. | |
| JP2020012850A5 (enExample) | ||
| CY1121741T1 (el) | Χρηση του μεγεθους θραυσματων εξωκυτταριου dna για τον προσδιορισμο παραλλαγης αριθμου αντιγραφων | |
| CR20150437A (es) | Construcciones de anticuerpos para cdh19 y cd3 | |
| GB2547838A (en) | Method and system for improved classification of constituent materials | |
| TR201900160T4 (tr) | Bir anti-ilaç antikoru varlığının veya miktarının saptanmasına yönelik analizler. | |
| MX392706B (es) | Ensayo a base de células para detectar homodímeros anti-cd3. | |
| BR112016004437A2 (pt) | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit | |
| WO2016046640A3 (en) | Methods for predicting drug responsiveness | |
| CA2951016C (en) | Prostate cancer detection kit or device, and detection method | |
| JP2018514210A5 (enExample) | ||
| EA201892325A1 (ru) | Композиции и способы детектирования белков клетки-хозяина | |
| WO2015088927A3 (en) | Access tracking and restriction | |
| EA201792289A1 (ru) | Способы обнаружения агглютинации и композиции для их осуществления | |
| CY1125342T1 (el) | Μεθοδοι για την ανιχνευση και/ή μετρηση αντισωματων εναντι των αντισωματων φαρμακου, ιδιως αντισωματων εναντι των αντισωματων φαρμακου προκυπτοντων κατα τη θεραπευτικη αγωγη | |
| MX2017006831A (es) | Sistemas y metodos para la determinacion electroquimica de hematocrito mediante determinaciones de angulos de fase de impedancia de corriente alterna. | |
| MX2021002166A (es) | Metodos de deteccion basados en acido nucleico. | |
| JP2017534851A5 (enExample) | ||
| BR112014012003A2 (pt) | sistema de controle de qualidade, método e meio legível por computador para o uso com bens de consumo, usuários e dispositivos de teste de diagnóstico biológico/ambiental | |
| MX2018004029A (es) | Deteccion de analitos con multiples sustratos. | |
| JP2019518443A5 (enExample) |